Biotech Values

[mouton29]

For Paxlovid, the label is similarly "restricted" to adults who are at high risk for progression to severe COVID-19. The label lists 12 specific conditions or factors that place a patient at high risk and then proceeds add a catch-all giving the “healthcare provider” even more discretion:

Other medical conditions or factors (e.g., race or ethnicity) may also place individual patients
at high risk for progression to severe COVID-19 and are not limited to the medical conditions
or factors listed above. Healthcare providers should consider the benefit-risk for an individual
patient

.


https://labeling.pfizer.com/ShowLabeling.aspx?id=19730#page2

In contrast the Nuvaxovid label provides no definition of high risk.  

https://www.fda.gov/media/186544/download?attachment

I think in practice, the prescribing doctor makes the decision when he or she decides to write the prescription; I can't imagine a pharmacist refusing to fill a prescription.